GeoVax Labs (GOVX)
(Delayed Data from NSDQ)
$1.61 USD
+0.19 (13.38%)
Updated May 3, 2024 03:59 PM ET
After-Market: $1.59 -0.02 (-1.24%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
GeoVax Labs Inc. [GOVX]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Reports Full Year 2023 - $6.5M in Cash, Expect a Raise, The Project NextGen (Covid) Award from BARDA Could be a Key Catalyst
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Model Revised Introducing a $5.0 Price Target
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
1 for 15 Reverse Split Effected, Model Under Review
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Enters a Common Stock Warrant Exercise - $4.4M Expected
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results: Recent Milestones Position Clinical Programs for Important Near-Term Data Readouts; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs: Reported the Quarter - Data Ahead
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs: Expands Clinical Sites for P2 COVID Vaccine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Notice of Patent Allowance For Marburg Further Expands Freedom to Operate; Reiterate Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs Secures License for ProBioGen''s Manufacturing
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
GeoVax Labs Announces Publication of GEO-CM04S1 Data
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Completes Enrollment of P2 for COVID-19 Booster
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Notable 1H23 Achievements Set the Stage For Future Success; Reiterate Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Is Malaria Back? GeoVax Picks Up Malaria IP
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Reports 2nd Quarter Highlights Clinical Progress
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Company: GeoVax Labs Inc.
Industry: Medical - Biomedical and Genetics
Start of a Phase II Trial: COVID-19 Vaccine Booster in Chronic Lymphocytic Leukemia Patients
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J